Compare Humana Inc (HUM) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Tesla, Inc. — how do they compare? Humana Inc trades at $437.71 (market cap $46.49B), while Tesla, Inc. trades at $384.41 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 31.8× Humana Inc's market cap, and Humana Inc pays a 0.91% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Tesla, Inc. for 88 Days on average.
| HUM | TSLA | |
|---|---|---|
Market Cap | $46.49B | $1.48T |
Volume | 2,567,704 | 28,215,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $409.85 | $489.88 |
52-Week Low | $163.67 | $298.16 |
Typical Hold Time | 53 Days | 88 Days |
Enterprise Value | $53.84B | $1.45T |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $441.74, up 11.41% over 24 hours, reflecting strong momentum. The stock shows bullish technical signals with support at $391 and resistance at $406. Fundamentally, revenue grew to $129.66B in 2025, though net income margin compressed to 0.88%. Recent news highlights a Barclays upgrade to a $515 price target and upcoming Q3 earnings on November 6, 2026.
The outlook is cautiously optimistic with a consensus price target of $457.05 implying modest upside. Risks include margin pressure from Medicare Advantage plan changes and potential regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes.
Tesla (TSLA) trades at $377.61, down 0.81% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported mixed Q2 2026 earnings, missing EPS estimates, while revenue has softened slightly in 2025. Analyst consensus remains positive with a $441.36 price target, and recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch.
Tesla's outlook balances innovation in autonomy and energy against near-term earnings pressure and high valuations. Investment opportunities lie in AI and robotaxi growth, but risks include intense EV competition, execution on new technologies, and profitability concerns given a P/E of 347.22. The stock's performance hinges on delivering future growth to justify its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
